Search
crovalimab (Piasky)
Indications:
- paroxysmal nocturnal hemoglobinuria*
* adults & childen >= 40 kg (88 lbs)
Dosage:
- meningococcal vaccination prior to 1st dose
- after a series of loading doses,
- maintenance: subcutaneous injection every 4 weeks.
- dosage is weight-dependent, refer to Highlights of Prescribing Information [2]
Adverse effects:
- infusion-related reactions
- infections (respiratory tract infections & viral infectionz)
- Type 3 hypersensitivity reactions
- boxed warning:
- life-threatening infections caused by Neisseria meningitidis
Mechanism of action:
- complement C5 inhibitor
- engineered to be recycled in the bloodstream to sustain responses
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- Ingram I
Subcutaneous C5 Inhibitor Approved for PNH. Longer-acting crovalimab designed for
more sustained effect and less treatment burden.
MedPage Today June 24, 2024
https://www.medpagetoday.com/hematologyoncology/hematology/110793
- Highlights of Prescribing Information*
PIASKY (crovalimab-akkz) injection, for intravenous or subcutaneous use
https://www.gene.com/download/pdf/piasky_prescribing.pdf